NewAmsterdam Pharma Valuation Multiples

NewAmsterdam Pharma Overview

About NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Founded

2019

HQ

Employees

100

Website

newamsterdampharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $24M

EBITDA: ($226M)

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

NewAmsterdam Pharma Financials

NewAmsterdam Pharma reported last 12-month revenue of $24M and negative EBITDA of ($226M).

In the same LTM period, NewAmsterdam Pharma generated $24M in gross profit, ($226M) in EBITDA losses, and had net loss of ($210M).

NewAmsterdam Pharma P&L

In the most recent fiscal year, NewAmsterdam Pharma reported revenue of $23M and EBITDA of ($225M).

NewAmsterdam Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma has current market cap of $4B, and enterprise value of $3B.

NewAmsterdam Pharma's stock price is $31.18.

NewAmsterdam Pharma Valuation Multiples

NewAmsterdam Pharma trades at 124.2x EV/Revenue multiple, and (13.1x) EV/EBITDA.

NewAmsterdam Pharma Financial Valuation Multiples

As of March 7, 2026, NewAmsterdam Pharma has market cap of $4B and EV of $3B.

Equity research analysts estimate NewAmsterdam Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

NewAmsterdam Pharma has a P/E ratio of (17.1x).

NewAmsterdam Pharma Margins & Growth Rates

NewAmsterdam Pharma's revenue in the last 12 month grew by 141%.

NewAmsterdam Pharma's revenue per employee in the last FY averaged $0.2M.

NewAmsterdam Pharma's rule of 40 is (811%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

NewAmsterdam Pharma's rule of X is (600%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

NewAmsterdam Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

NewAmsterdam Pharma M&A Activity

NewAmsterdam Pharma acquired XXX companies to date.

Last acquisition by NewAmsterdam Pharma was on XXXXXXXX, XXXXX. NewAmsterdam Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

NewAmsterdam Pharma Investment Activity

NewAmsterdam Pharma invested in XXX companies to date.

NewAmsterdam Pharma made its latest investment on XXXXXXXX, XXXXX. NewAmsterdam Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).